North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations : Part I: Diagnosis, evaluation, and the use of complementary and procedural management - 21/06/19
Doi : 10.1016/j.jaad.2019.02.067
Ali Alikhan, MD a : Co-chair, Christopher Sayed, MD b, ⁎ 
: Co-chair, Afsaneh Alavi, MD, MSc c, Raed Alhusayen, MD c, Alain Brassard, MD d, Craig Burkhart, MD b, Karen Crowell, MLIS e, Daniel B. Eisen, MD d, Alice B. Gottlieb, MD, PhD f, Iltefat Hamzavi, MD g, Paul G. Hazen, MD h, Tara Jaleel, MD i, Alexa B. Kimball, MD, MPH j, Joslyn Kirby, MD, MEd, MS k, Michelle A. Lowes, MBBS, PhD l, Robert Micheletti, MD m, n, Angela Miller, CCRP, CWCA g, Haley B. Naik, MD, MHSc o, Dennis Orgill, MD p, Yves Poulin, MD q
: Co-chair, Afsaneh Alavi, MD, MSc c, Raed Alhusayen, MD c, Alain Brassard, MD d, Craig Burkhart, MD b, Karen Crowell, MLIS e, Daniel B. Eisen, MD d, Alice B. Gottlieb, MD, PhD f, Iltefat Hamzavi, MD g, Paul G. Hazen, MD h, Tara Jaleel, MD i, Alexa B. Kimball, MD, MPH j, Joslyn Kirby, MD, MEd, MS k, Michelle A. Lowes, MBBS, PhD l, Robert Micheletti, MD m, n, Angela Miller, CCRP, CWCA g, Haley B. Naik, MD, MHSc o, Dennis Orgill, MD p, Yves Poulin, MD q a Sutter Health, Sacramento, California
b Department of Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
c Department of Medicine, Division of Dermatology, University of Toronto, Toronto, Ontario, Canada
d Department of Dermatology, University of California at Davis, Sacramento, California
e Health Sciences Library, University of North Carolina School of Medicine, Chapel Hill, North Carolina
f Department of Dermatology, Icahn School of Medicine at Mt Sinai Hospital, New York, New York
g Department of Dermatology, Henry Ford Hospital, Detroit, Michigan
h Associates in Dermatology, Westlake, Ohio
i Department of Dermatology, Duke University School of Medicine, Durham, North Carolina
j Department of Dermatology, Harvard Medical School, Boston, Massachusetts
k Department of Dermatology, Penn State Hershey Medical Center, Hershey, Pennsylvania
l Laboratory for Investigative Dermatology, New York, New York
m Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
n Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
o Department of Dermatology, University of California San Francisco, San Francisco, California
p Division of Plastic Surgery, Brigham and Women's Hospital, Boston, Massachusetts
q Centre de Recherche Dermatologique du Quebec Metropolitain, Quebec City, Quebec, Canada
∗Correspondence to: Christopher Sayed, MD, University of North Carolina Dermatology, 410 Market St, Suite 400, Chapel Hill, NC, 27516.University of North Carolina Dermatology410 Market St, Suite 400Chapel HillNC27516
Abstract |
Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life. Evidence informing ideal evaluation and management of patients with hidradenitis suppurativa is still sparse in many areas, but it has grown substantially in the last decade. Part I of this evidence-based guideline is presented to support health care practitioners as they select optimal management strategies, including diagnostic testing, comorbidity screening, and both complementary and procedural treatment options. Recommendations and evidence grading based on the evidence available at the time of the review are provided.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, adalimumab, biomarkers, carbon dioxide laser, clindamycin, comorbidities, ertapenem, finasteride, guidelines, hidradenitis suppurativa, infliximab, laser, lifestyle modification, microbiome, Nd:YAG, oral contraceptive pills, rifampin, spironolactone
Abbreviations used : DLQI, HS, IL
Plan
| Dr Alikhan and Dr Sayed are cofirst authors. |
|
| Funding sources: None. |
|
| Disclosure: Dr Sayed reports service as a speaker for AbbVie and Novartis, an advisory board member for AbbVie and InflaRx, a coinvestigator for AbbVie and Novartis, and an investigator for InflaR and UCB. Dr Hamzavi reports service as an investigator for AbbVie, The Microdermis Corporation, Adelphi Values, and Lenicura and a consultant for UCB and Incyte; in addition, he is president of the Hidradenitis Suppurativa Foundation. Dr Hazen reports service as a speaker for AbbVie and an advisory board member for AbbVie. Dr Kimball reports service as a consultant and investigator for Amgen, AbbVie, Janssen, and Novartis and has received fellowship funding from Novarti and AbbVie. Dr Lowes reports service as an advisory board member for AbbVie and Janssen and a consultant for AbbVie, XBiotech, and Incyte. Dr Alavi reports service as a clinical investigator and consultant for AbbVie, Janssen, Novartis, Pfizer, Galderma, Leo, and Valeant and has received grant funding from AbbVie. Dr Naik reports grant funding from AbbVie. Dr Alhusayen reports service for AbbVie as an advisory board member and consulting and has received research funding from the company; he has also served as an advisory board member for Janssen and a consultant for Eli Lilly and Company and Hidramed Solutions. Dr Orgill has served as a consultant and investigator for KCI, Inc, and Integra. Dr Brassard has served as a speaker and advisory board member for AbbVie, Janssen, Celgene, and 3M and as a speaker for Coloplast and Hollister. Dr Miller has served as a consultant for AbbVie and an advisory board member for AbbVie and BSN; in addition, she is employed by the Hidradenitis Suppurativa Foundation and is president and founding director of the Hope for HS support group. Dr Poulin has served as an investigator, advisory board member, and speaker for AbbVie. Dr Kirby has served as an advisory board member and speaker for AbbVie and a consultant for Incyte and Chemocentryx. Dr Gottlieb has served as an investigator for Novartis and a speaker for AbbVie. Dr Jaleel has served as an investigator for Eli Lilly and Company. Dr Alikhan, Dr Micheletti, Dr Eisen, Dr Burkhart, and Dr Crowell have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 81 - N° 1
P. 76-90 - juillet 2019 Retour au numéro
Article précédent
- Eosinophilic dermatosis of hematologic malignancy: Reality bites
- Warren R. Heymann
- North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations : Part II: Topical, intralesional, and systemic medical management
- Ali Alikhan, Christopher Sayed, Afsaneh Alavi, Raed Alhusayen, Alain Brassard, Craig Burkhart, Karen Crowell, Daniel B. Eisen, Alice B. Gottlieb, Iltefat Hamzavi, Paul G. Hazen, Tara Jaleel, Alexa B. Kimball, Joslyn Kirby, Michelle A. Lowes, Robert Micheletti, Angela Miller, Haley B. Naik, Dennis Orgill, Yves Poulin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?